Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.5K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.5K
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

984
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
984
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

711
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
711
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

1.2K
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Altered aperiodic EEG spectral power during speech perception task is associated with verbal communication in youths with Autism Spectrum Disorder.

Scientific reports·2026
Same author

A novel fixel-based approach for resolving neonatal white matter microstructure from clinical diffusion MRI.

Frontiers in neuroscience·2026
Same author

Excess EEG beta-band oscillations in Dup15q syndrome correlate with clinical severity.

Translational psychiatry·2026
Same author

Contextualizing Socioeconomic Status Effects on Adolescent Brain Structure and Cognitive Skills: Evidence From the ABCD Study.

Developmental science·2026
Same author

Behavioral Assessment Reliability in Clinical Phenotyping and Biomarker Research for Autism.

medRxiv : the preprint server for health sciences·2026
Same author

Enhancing Fetal Brain Imaging: ALPS-FMEG Technique Achieves Accurate Signal Extraction by Mitigating Movement Artifacts.

Annals of biomedical engineering·2026

Related Experiment Video

Updated: May 5, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K

Reviewing the ketamine model for schizophrenia.

Joel Frohlich1, John D Van Horn

  • 11UCLA Center for Autism Research and Treatment (CART), University of California, Los Angeles, CA, USA.

Journal of Psychopharmacology (Oxford, England)
|November 22, 2013
PubMed
Summary

Ketamine and phencyclidine (PCP) reveal N-methyl-D-aspartate receptor (NMDAR) hypofunction in schizophrenia. This glutamate dysfunction explains key symptoms and abnormalities, offering new research avenues.

Keywords:
KetamineN-methyl-D-aspartate receptorglutamateschizophrenia

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.8K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.2K

Related Experiment Videos

Last Updated: May 5, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.8K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.2K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia research has shifted from dopamine to glutamate dysfunction, prompted by N-methyl-D-aspartate receptor (NMDAR) antagonists like PCP and ketamine inducing schizophrenia-like symptoms.
  • The glutamate hypothesis offers a more comprehensive explanation for schizophrenia's negative and cognitive symptoms compared to the dopamine hypothesis.

Purpose of the Study:

  • To review the pharmacological and psychomimetic effects of ketamine as a safer alternative to PCP for studying schizophrenia.
  • To explore the role of NMDAR hypofunction in the pathophysiology of schizophrenia, including its impact on various symptoms and neural dysfunctions.

Main Methods:

  • Review of existing literature on ketamine's receptor binding and psychotomimetic effects.
  • Analysis of genetic and molecular evidence implicating NMDAR hypofunction in schizophrenia.
  • Examination of how NMDAR hypofunction explains network abnormalities, including GABAergic interneuron function and cortical oscillations.

Main Results:

  • Ketamine primarily acts on NMDARs, and evidence strongly supports NMDAR hypofunction in schizophrenia.
  • NMDAR hypofunction can account for weakened excitation of inhibitory interneurons, leading to disinhibition of principal cells and abnormal cortical network synchronization.
  • Prenatal NMDAR aberrations may contribute to schizophrenia onset during adolescence due to critical drops in network connectivity post-synaptic pruning.

Conclusions:

  • Ketamine challenge is a valuable tool for investigating positive, negative, and cognitive symptoms of schizophrenia.
  • This model aids in studying associated dopaminergic and GABAergic dysfunctions, age of onset, functional dysconnectivity, and abnormal cortical oscillations in schizophrenia.